Clinical Trials Logo

Filter by:
NCT ID: NCT00643448 Completed - Atrial Fibrillation Clinical Trials

Explorative Study of AZD1305 in Atrial Fibrillation Patients

Start date: March 2008
Phase: Phase 2
Study type: Interventional

Explorative study in Atrial Fibrillation patients to assess Safety and Pharmacokinetics at initiation of treatment and at steady state

NCT ID: NCT00643409 Completed - Maxillary Sinusitis Clinical Trials

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The objectives of the study were to confirm that a single, 2.0-g dose of azithromycin sustained release (SR) was at least as effective to 10 days of oral levofloxacin 500 mg once a day, when used to treat adults with uncomplicated, acute bacterial sinus infections, and to evaluate the safety of both treatments.

NCT ID: NCT00643292 Completed - Acute Otitis Media Clinical Trials

A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections

Start date: January 2003
Phase: Phase 3
Study type: Interventional

A phase 3 randomized, multicenter, double blind, double dummy study to assess the efficacy, safety, and compliance of a single dose of azithromycin extended release compared with a 10-day course of amoxicillin/clavulanate twice daily in children at high risk for persistent or recurrent ear infections

NCT ID: NCT00643227 Completed - Pneumonia Clinical Trials

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Clarithromycin Extended Release for the Treatment of Pneumonia in Adult Patients

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The study was performed to confirm that a single, 2.0 g oral dose of azithromycin sustained release (SR) at least as effective as 7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily, when used to treat adults with mild to moderate community acquired pneumonia (CAP), and that both treatments were safe.

NCT ID: NCT00643201 Completed - Venous Thrombosis Clinical Trials

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

Start date: July 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE)

NCT ID: NCT00643188 Completed - Heart Failure Clinical Trials

Catheter Ablation vs. Standard Conventional Treatment in Patients With LV Dysfunction and AF

CASTLE-AF
Start date: January 2008
Phase: Phase 4
Study type: Interventional

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. The incidence and prevalence of AF increase exponentially with increasing age and AF is associated with higher mortality, more frequent hospitalization, and lower quality of life. Furthermore, AF is often associated with heart failure. The majority of AF is initiated by ectopic foci found primarily in the pulmonary veins. It was shown that catheter ablation of those veins could eliminate episodes of AF. In patients with heart failure, catheter ablation could improve cardiac function, symptoms and quality of life. It remains still unknown whether AF ablation is more effective than conventional treatment in terms of mortality and morbidity.

NCT ID: NCT00642681 Completed - Diabetes Mellitus Clinical Trials

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

Start date: December 2007
Phase: Phase 2
Study type: Observational

Effect of upper respiratory infection (URI) on diabetic subjects with a meal challenge

NCT ID: NCT00642278 Completed - Clinical trials for Diabetes Mellitus, Type II

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Start date: April 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness, safety, and tolerability of JNJ-28431754 compared with placebo in patients with type 2 diabetes.

NCT ID: NCT00642148 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Start date: February 14, 2008
Phase: Phase 2
Study type: Interventional

Phase IIa, randomised, double-blind, double-dummy, parallel group, multi-centre study in subjects diagnosed with moderate chronic obstructive pulmonary disease (COPD). The primary objective is to evaluate the effects of 12-weeks of treatment with GW856553 7.5 mg twice daily (BID) compared with placebo on the percentage of sputum neutrophils at 12 weeks. Twelve weeks of treatment with SERETIDE 50/500 BID will be compared with placebo for effect on sputum neutrophils as a positive control arm in the study

NCT ID: NCT00641537 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis

CLARITY Extension Study

Start date: February 29, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week treatment.